TMB-话题@MedSci - williamhill asia

#TMB#

15篇内容 | 1055人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2204600, encodeId=bef5220460090, content=<a href='/topic/show?id=18d293422fd' target=_blank style='color:#2F92EE;'>#转移性结直肠癌#</a> <a href='/topic/show?id=56581e550e3' target=_blank style='color:#2F92EE;'>#TMB#</a> <a href='/topic/show?id=7b2910612398' target=_blank style='color:#2F92EE;'>#度伐利尤单抗#</a> <a href='/topic/show?id=be5510e738c0' target=_blank style='color:#2F92EE;'>#曲美木单抗#</a>, objectTitle=CLIN CANCER RES：血浆与组织TMB作为度伐利尤单抗加曲美木单抗对转移性结直肠癌患者反应的生物标志物研究, objectType=article, longId=825722, objectId=0aac825e2287, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240512/1715513188767_5579292.png, objectUrl=/article/show_article.do?id=0aac825e2287, replyNumber=0, likeNumber=29, createdTime=2024-05-14, rootId=0, userName=williamhill asia 管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=0aac825e2287, moduleTitle=CLIN CANCER RES：血浆与组织TMB作为度伐利尤单抗加曲美木单抗对转移性结直肠癌患者反应的生物标志物研究, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=0aac825e2287)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1642636, encodeId=0fbc164263630, content=<a href='/topic/show?id=56581e550e3' target=_blank style='color:#2F92EE;'>#TMB#</a>, objectTitle=Cancer Discov：Atezolizumab治疗高TMB肿瘤患者的疗效：MyPathway研究, objectType=article, longId=265038, objectId=9aa526503837, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9aa526503837, replyNumber=0, likeNumber=97, createdTime=2022-04-08, rootId=0, userName=ms3025846204744509, userId=9d7922995041, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9aa526503837, moduleTitle=Cancer Discov：Atezolizumab治疗高TMB肿瘤患者的疗效：MyPathway研究, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=9aa526503837)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642638, encodeId=3853164263803, content=<a href='/topic/show?id=56581e550e3' target=_blank style='color:#2F92EE;'>#TMB#</a>, objectTitle=AACR 2022：TMB不能成为好的免疫检查点抑制剂的biomarker (RATIONALE 304研究)?, objectType=article, longId=724034, objectId=348fe24034fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=348fe24034fa, replyNumber=0, likeNumber=0, createdTime=2022-09-25, rootId=0, userName=ms3025846204744509, userId=9d7922995041, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=348fe24034fa, moduleTitle=AACR 2022：TMB不能成为好的免疫检查点抑制剂的biomarker (RATIONALE 304研究)?, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=348fe24034fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642635, encodeId=4e1e16426354d, content=<a href='/topic/show?id=56581e550e3' target=_blank style='color:#2F92EE;'>#TMB#</a>, objectTitle=Front Oncol：TMB状态对抗HER2治疗在HER2阳性晚期胃癌(AGC)的疗效的影响, objectType=article, longId=221553, objectId=243b2215533b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=243b2215533b, replyNumber=0, likeNumber=105, createdTime=2022-10-03, rootId=0, userName=ms3025846204744509, userId=9d7922995041, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=243b2215533b, moduleTitle=Front Oncol：TMB状态对抗HER2治疗在HER2阳性晚期胃癌(AGC)的疗效的影响, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=243b2215533b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642637, encodeId=d89d164263edc, content=<a href='/topic/show?id=56581e550e3' target=_blank style='color:#2F92EE;'>#TMB#</a>, objectTitle=AACR重磅之RATIONALE-304：肿瘤突变负荷（TMB）与替雷利珠单抗（TIS）+化疗（chemo）与单独化疗在晚期非鳞状非小细胞肺癌（nsq-NSCLC）一线治疗的临床结局研究, objectType=article, longId=723964, objectId=100be239645b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=100be239645b, replyNumber=0, likeNumber=144, createdTime=2022-10-20, rootId=0, userName=ms3025846204744509, userId=9d7922995041, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=100be239645b, moduleTitle=AACR重磅之RATIONALE-304：肿瘤突变负荷（TMB）与替雷利珠单抗（TIS）+化疗（chemo）与单独化疗在晚期非鳞状非小细胞肺癌（nsq-NSCLC）一线治疗的临床结局研究, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=100be239645b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642634, encodeId=858516426344f, content=<a href='/topic/show?id=56581e550e3' target=_blank style='color:#2F92EE;'>#TMB#</a>, objectTitle=Cancer Immunol Immunother：肿瘤突变评分(TMS)取代肿瘤突变负荷(TMB)预测NSCLC患者对ICI治疗的反应性？, objectType=article, longId=206834, objectId=5369206834ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5369206834ca, replyNumber=0, likeNumber=74, createdTime=2021-11-07, rootId=0, userName=ms3025846204744509, userId=9d7922995041, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5369206834ca, moduleTitle=Cancer Immunol Immunother：肿瘤突变评分(TMS)取代肿瘤突变负荷(TMB)预测NSCLC患者对ICI治疗的反应性？, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=5369206834ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642633, encodeId=c66e1642633fd, content=<a href='/topic/show?id=56581e550e3' target=_blank style='color:#2F92EE;'>#TMB#</a>, objectTitle=Nat Commun：新进展！抑制TMBIM6基因可抑制原发性肿瘤的生长, objectType=article, longId=199640, objectId=d76d1996404f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d76d1996404f, replyNumber=0, likeNumber=64, createdTime=2021-01-22, rootId=0, userName=ms3025846204744509, userId=9d7922995041, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d76d1996404f, moduleTitle=Nat Commun：新进展！抑制TMBIM6基因可抑制原发性肿瘤的生长, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=d76d1996404f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642632, encodeId=02c11642632ce, content=<a href='/topic/show?id=56581e550e3' target=_blank style='color:#2F92EE;'>#TMB#</a>, objectTitle=肿瘤突变评分预测免疫治疗预后可能优于TMB, objectType=article, longId=184140, objectId=1d0818414097, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d0818414097, replyNumber=0, likeNumber=71, createdTime=2020-03-18, rootId=0, userName=ms3025846204744509, userId=9d7922995041, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d0818414097, moduleTitle=肿瘤突变评分预测免疫治疗预后可能优于TMB, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=1d0818414097)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642628, encodeId=fa351642628c0, content=<a href='/topic/show?id=56581e550e3' target=_blank style='color:#2F92EE;'>#TMB#</a>, objectTitle=实体瘤患者PD-L1表达与TMB、MSI的相关性研究, objectType=article, longId=168267, objectId=22fc16826e29, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22fc16826e29, replyNumber=0, likeNumber=70, createdTime=2020-04-29, rootId=0, userName=ms3025846204744509, userId=9d7922995041, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22fc16826e29, moduleTitle=实体瘤患者PD-L1表达与TMB、MSI的相关性研究, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=22fc16826e29)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642631, encodeId=7592164263115, content=<a href='/topic/show?id=56581e550e3' target=_blank style='color:#2F92EE;'>#TMB#</a>, objectTitle=FDA批准针对TMB的癌症全外显子组临床基因检测产品, objectType=article, longId=183019, objectId=24cc183019c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24cc183019c5, replyNumber=0, likeNumber=0, createdTime=2020-07-17, rootId=0, userName=ms3025846204744509, userId=9d7922995041, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24cc183019c5, moduleTitle=FDA批准针对TMB的癌症全外显子组临床基因检测产品, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=24cc183019c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642629, encodeId=ded716426290a, content=<a href='/topic/show?id=56581e550e3' target=_blank style='color:#2F92EE;'>#TMB#</a>, objectTitle=OncoImmunology：超10万肿瘤患者大规模荟萃分析，再证TMB免疫治疗疗效预测价值！, objectType=article, longId=174899, objectId=30621e489904, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=30621e489904, replyNumber=0, likeNumber=70, createdTime=2019-08-07, rootId=0, userName=ms3025846204744509, userId=9d7922995041, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=30621e489904, moduleTitle=OncoImmunology：超10万肿瘤患者大规模荟萃分析，再证TMB免疫治疗疗效预测价值！, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=30621e489904)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642630, encodeId=95821642630fc, content=<a href='/topic/show?id=56581e550e3' target=_blank style='color:#2F92EE;'>#TMB#</a>, objectTitle=JAMA Oncol:高TMB，高irAE风险, objectType=article, longId=178978, objectId=3c4b1e89789c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c4b1e89789c, replyNumber=0, likeNumber=60, createdTime=2020-03-18, rootId=0, userName=ms3025846204744509, userId=9d7922995041, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c4b1e89789c, moduleTitle=JAMA Oncol:高TMB，高irAE风险, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=3c4b1e89789c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642627, encodeId=e3d1164262e59, content=<a href='/topic/show?id=56581e550e3' target=_blank style='color:#2F92EE;'>#TMB#</a>, objectTitle=Fred Hirsch教授：TMB检测尚无法准确预测免疫治疗疗效, objectType=article, longId=154860, objectId=1344154860c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1344154860c1, replyNumber=0, likeNumber=54, createdTime=2019-03-01, rootId=0, userName=ms3025846204744509, userId=9d7922995041, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1344154860c1, moduleTitle=Fred Hirsch教授：TMB检测尚无法准确预测免疫治疗疗效, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=1344154860c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642625, encodeId=113d16426255d, content=<a href='/topic/show?id=56581e550e3' target=_blank style='color:#2F92EE;'>#TMB#</a>, objectTitle=Cancer Cell：TMB标志物显神威！可增加小细胞肺癌I-O治疗有效性, objectType=article, longId=138254, objectId=49d8138254d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=49d8138254d3, replyNumber=0, likeNumber=77, createdTime=2019-04-15, rootId=0, userName=ms3025846204744509, userId=9d7922995041, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=49d8138254d3, moduleTitle=Cancer Cell：TMB标志物显神威！可增加小细胞肺癌I-O治疗有效性, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=49d8138254d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642626, encodeId=c63a16426260b, content=<a href='/topic/show?id=56581e550e3' target=_blank style='color:#2F92EE;'>#TMB#</a>, objectTitle=Nat Med：bTMB验证性文章今日发表，血检又进一步, objectType=article, longId=146151, objectId=f711146151a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f711146151a0, replyNumber=0, likeNumber=68, createdTime=2019-06-15, rootId=0, userName=ms3025846204744509, userId=9d7922995041, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f711146151a0, moduleTitle=Nat Med：bTMB验证性文章今日发表，血检又进一步, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=f711146151a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642624, encodeId=1a67164262424, content=<a href='/topic/show?id=56581e550e3' target=_blank style='color:#2F92EE;'>#TMB#</a>, objectTitle=[WCLC2017]胡洁教授深入解读ctDNA检测肿瘤突变负荷（TMB）在中国肺癌免疫治疗中的应用, objectType=article, longId=116642, objectId=d179116642cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d179116642cc, replyNumber=0, likeNumber=80, createdTime=2018-06-17, rootId=0, userName=ms3025846204744509, userId=9d7922995041, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d179116642cc, moduleTitle=[WCLC2017]胡洁教授深入解读ctDNA检测肿瘤突变负荷（TMB）在中国肺癌免疫治疗中的应用, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=d179116642cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] williamhill asia 话题小助手

TMB

2020-05-29

williamhill asia 管理员 (审核中...)

前往app查看评论内容

#转移性结直肠癌# #TMB# #度伐利尤单抗# #曲美木单抗#

CLIN CANCER RES：血浆与组织TMB作为度伐利尤单抗加曲美木单抗对转移性结直肠癌患者反应的生物标志物研究

2024-05-14发表于上海

ms3025846204744509 (审核中...)

前往app查看评论内容

#TMB#

Cancer Discov：Atezolizumab治疗高TMB肿瘤患者的疗效：MyPathway研究

2022-04-08

ms3025846204744509 (审核中...)

前往app查看评论内容

#TMB#

AACR 2022：TMB不能成为好的免疫检查点抑制剂的biomarker (RATIONALE 304研究)?

2022-09-25

ms3025846204744509 (审核中...)

前往app查看评论内容

#TMB#

Front Oncol：TMB状态对抗HER2治疗在HER2阳性晚期胃癌(AGC)的疗效的影响

2022-10-03

ms3025846204744509 (审核中...)

前往app查看评论内容

#TMB#

AACR重磅之RATIONALE-304：肿瘤突变负荷（TMB）与替雷利珠单抗（TIS）+化疗（chemo）与单独化疗在晚期非鳞状非小细胞肺癌（nsq-NSCLC）一线治疗的临床结局研究

2022-10-20

ms3025846204744509 (审核中...)

前往app查看评论内容

#TMB#

Cancer Immunol Immunother：肿瘤突变评分(TMS)取代肿瘤突变负荷(TMB)预测NSCLC患者对ICI治疗的反应性？

2021-11-07

ms3025846204744509 (审核中...)

前往app查看评论内容

#TMB#

Nat Commun：新进展！抑制TMBIM6基因可抑制原发性肿瘤的生长

2021-01-22

ms3025846204744509 (审核中...)

前往app查看评论内容

#TMB#

肿瘤突变评分预测免疫治疗预后可能优于TMB

2020-03-18

ms3025846204744509 (审核中...)

前往app查看评论内容

#TMB#

实体瘤患者PD-L1表达与TMB、MSI的相关性研究

2020-04-29

ms3025846204744509 (审核中...)

前往app查看评论内容

#TMB#

FDA批准针对TMB的癌症全外显子组临床基因检测产品

2020-07-17

ms3025846204744509 (审核中...)

前往app查看评论内容

#TMB#

OncoImmunology：超10万肿瘤患者大规模荟萃分析，再证TMB免疫治疗疗效预测价值！

2019-08-07

ms3025846204744509 (审核中...)

前往app查看评论内容

#TMB#

JAMA Oncol:高TMB，高irAE风险

2020-03-18

ms3025846204744509 (审核中...)

前往app查看评论内容

#TMB#

Fred Hirsch教授：TMB检测尚无法准确预测免疫治疗疗效

2019-03-01

ms3025846204744509 (审核中...)

前往app查看评论内容

#TMB#

Cancer Cell：TMB标志物显神威！可增加小细胞肺癌I-O治疗有效性

2019-04-15

ms3025846204744509 (审核中...)

前往app查看评论内容

#TMB#

Nat Med：bTMB验证性文章今日发表，血检又进一步

2019-06-15

ms3025846204744509 (审核中...)

前往app查看评论内容

#TMB#

[WCLC2017]胡洁教授深入解读ctDNA检测肿瘤突变负荷（TMB）在中国肺癌免疫治疗中的应用

2018-06-17

科室
- - 订阅+
  - 更多科室
工具
服务